 |
|
|
Gastrogard Syringe (pack of 7) |
|
For treatment of gastric ulcers in horses, including foals from 4 weeks old.
|
|
Presentation
Each syringe of GASTROGARD, containing 6.16 g of paste, delivers Omeprazole 2.279 g (37% w/w paste).
Uses
For treatment of gastric ulcers in horses, including foals from 4 weeks old.
|
|
Dosage and administration
GASTROGARD is effective in horses of various breeds and under different management conditions, foals as young as four weeks of age and weighing over 70 kg, and breeding stallions.
For oral administration
Treatment of gastric ulcers: one administration per day during 28 consecutive days at the dose rate of 4 mg omeprazole per kg body weight followed immediately by a dosage regimen of one administration per day during 30 consecutive days at the dose rate of 2 mg omeprazole per kg body weight, to reduce the recurrence of gastric ulcers during treatment.
Should recurrence occur (confirmed by gastroscopy), retreatment at a dose rate of 4 mg omeprazole per kg body weight is recommended.
To deliver GASTROGARD at the treatment dose of 4 mg omeprazole/kg, set the syringe plunger to the appropriate dose division for the horse’s weight. Each full dose division on the syringe plunger delivers sufficient omeprazole to treat 100 kg bodyweight. The contents of one syringe will treat a 575 kg horse at the rate of 4 mg omeprazole per kg body weight.
To deliver GASTROGARD at the dose of 2 mg omeprazole/kg, set the syringe plunger to the dose division equivalent to half the horse's body weight. At this dose, each full division on the syringe plunger will deliver sufficient omeprazole to treat 200 kg body weight. The contents of one syringe will treat two 575 kg horses at the rate of 2 mg omeprazole per kg body weight, or one 575 kg horse on two successive days.
Replace cap after use.
|
|
Contra-indications, warnings, etc
For animal treatment only.
Not recommended for animals under 4 weeks old or weighing less than 70 kg bodyweight.
Pregnancy and lactation: Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic effect. In the absence of data during pregnancy and lactation, the use of GASTROGARD in pregnant and lactating mares is not recommended.
Interactions: Omeprazole may delay the elimination of warfarin. No other interaction with medicines routinely used in the treatment of horses is expected, although interaction with drugs metabolised by liver enzymes cannot be excluded.
No undesirable effects related to treatment were observed following daily use for 91 days at omeprazole dosages up to 20 mg/kg in adult horses and in foals older than 2 months.
No undesirable effects (including on the semen quality or reproductive behaviour) related to treatment were observed following daily use for 71 days at an omeprazole dosage of 12 mg/kg in breeding stallions. No undesirable effects related to treatment were observed following daily use for 21 days at an omeprazole dosage of 40 mg/kg in adult horses.
Operator warnings: As this product may cause hypersensitivity in rare situations, avoid direct contact with skin and eyes. Use impervious gloves and do not eat or drink when handling and administering the product. Wash hands or any exposed skin after use. In case of contact with eyes, wash immediately with clean running water and seek medical advice. Persons developing a reaction after contact with the product should avoid handling the product in future.
Withdrawal periods
Withdrawal period for horse meat and offal: one day. Not permitted for use in mares producing milk for human consumption.
Pharmaceutical precautions
Keep out of reach of children. No specific storage conditions are required. Replace cap after use.
Dispose of any unused product and empty syringes in accordance with guidance from your local waste regulation authority.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
Carton box of 7 syringes.
Further information
Omeprazole is a proton pump inhibitor belonging to the substituted benzimidazole class of compounds.
It is part of the pharmacotherapeutic group of antacids, for treatment of peptic ulcers.
Omeprazole suppresses gastric acid secretion by specific inhibition of the H+/K+- ATPase enzyme system at the secretory surface of the parietal cell. The H+/K+- ATPase enzyme system is the acid (proton) pump within the gastric mucosa. Because H+/K+- ATPase is the final step involved in control of acid secretion, omeprazole blocks secretion irrespective of the stimulus. Omeprazole irreversibly binds to the gastric parietal cell H+/K+-ATPase enzyme that pumps hydrogen ions into the lumen of the stomach in exchange for potassium ions.
Stress (including high performance training and competition), feeding, management and husbandry practices may be associated with the development of gastric ulceration in horses. Individuals responsible for the well-being of horses should consider reducing the ulcerogenic challenge by modifying husbandry practices to achieve one or more of the following: reduced stress, reduced fasting, increased intake of roughage and access to grazing.
Marketing authorisation number
Vm 08327/4205.
|
|
|
